Phaseline

Targets › PEDF

PEDF (Pigment epithelium-derived factor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Feb 2028.

Neurotrophic protein; induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. (UniProt, P36955)

Open in Phaseline: the race on PEDF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NexTheraNT-101 ophthalmic solution
Pigment epithelium-derived factor (PEDF) in type I atelocollagen formulation
PEDFPhase 2Wet Age Related Macular DegenerationFeb 2028

Conditions

Wet Age Related Macular Degeneration (1)

Modalities

–

Companies

NexThera (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.